Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Withdrawn 1Terminated 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Glioblastoma 12Brain Neoplasms 6Gliosarcoma 5Astrocytoma 4Oligodendroglioma 3Recurrence 2Optic Nerve Glioma 2Glioma 2Diffuse Intrinsic Pontine Glioma 2Central Nervous System Neoplasms 2Medulloblastoma 1Lung Neoplasms 1Familial ependymoma 1Choroid Plexus Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Temozolomide 23Bevacizumab 18Cyclophosphamide 9Carboplatin 7Lomustine 6Irinotecan 63-Iodobenzylguanidine 6Topotecan 5Radiotherapy 5Filgrastim 5Radiosurgery 4Nivolumab 4Everolimus 4Etoposide 4Busulfan 4sonidegib 3pembrolizumab 3olaparib 3fludarabine phosphate 3fludarabine 3antineoplaston AS 2-1 3antineoplaston A10 3Vincristine 3Thiotepa 3Sirolimus 3Melphalan 3IL13-PE38 3Drug Therapy 3Antilymphocyte Serum 3verubulin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recurrence × Cilengitide × CNS × Clear all
NCT01782976 2018-01-19

Ph II Cilengitide Plus Bevacizumab for Recurrent Glioblastoma (GBM)

M.D. Anderson Cancer Center

Phase 2 Withdrawn
CNS

Glioblastoma, Recurrence

NCT01517776 2015-07-21

HGG-CilMetro

Martin-Luther-Universität Halle-Wittenberg

Phase 2 Terminated
28 enrolled
CNS

Diffuse Intrinsic Pontine Glioma, Astrocytoma, Glioblastoma, Glioma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡